Last reviewed · How we verify
NCT06825780
Short Term Outcomes of Primary Percutaneous Coronary Intervention (PCI) Patients Presented With Acute Heart Failure in Assuit University Heart Hospital
trial in Primary Percutaneous Coronary Intervention in 200 participants. Not yet recruiting.
1 January 2026
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 3 March 2025 |
| Primary completion | 1 January 2026 |
| Estimated completion | 1 January 2026 |
| Sites | 1 location across Egypt |
Conditions studied
- Primary Percutaneous Coronary Intervention — all drugs for Primary Percutaneous Coronary Intervention →
Sponsor
Assiut University
Who can join
18 and older, any sex, with Primary Percutaneous Coronary Intervention. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Observational study outcome of PCI in patients presented with acute heart failure
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06825780
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Primary Percutaneous Coronary Intervention
Currently open trials in the same condition.
- NCT05510661 — Use of Export in Primary Percutaneous Coronary Intervention · NA · active not recruiting
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06825780 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 13 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06825780.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing